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ABSTRACT
Mucormycosis is the third invasive mycosis in order of importance after candidiasis and aspergillosis
and is caused by fungi of the class Zygomycetes. The most important species in order of frequency is
Rhizopus arrhizus (oryzae). Identiﬁcation of the agents responsible for mucormycosis is based on
macroscopic and microscopic morphological criteria, carbohydrate assimilation and the maximum
temperature compatible with its growth. The incidence of mucormycosis is approximately 1.7 cases per
1000 000 inhabitants per year, and the main risk-factors for the development of mucormycosis are
ketoacidosis (diabetic or other), iatrogenic immunosuppression, use of corticosteroids or deferoxamine,
disruption of mucocutaneous barriers by catheters and other devices, and exposure to bandages
contaminated by these fungi. Mucorales invade deep tissues via inhalation of airborne spores,
percutaneous inoculation or ingestion. They colonise a high number of patients but do not cause
invasion. Mucormycosis most commonly manifests in the sinuses (39%), lungs (24%), skin (19%),
brain (9%), and gastrointestinal tract (7%), in the form of disseminated disease (6%), and in other sites
(6%). Clinical diagnosis of mucormycosis is difﬁcult, and is often made at a late stage of the disease or
post-mortem. Conﬁrmation of the clinical form requires the combination of symptoms compatible with
histological invasion of tissues. The probable diagnosis of mucormycosis requires the combination of
various clinical data and the isolation in culture of the fungus from clinical samples. Treatment of
mucormycosis requires a rapid diagnosis, correction of predisposing factors, surgical resection,
debridement and appropriate antifungal therapy. Liposomal amphotericin B is the therapy of choice for
this condition. Itraconazole is considered to be inappropriate and there is evidence of its failure in
patients suffering from mucormycosis. Voriconazole is not active in vitro against Mucorales, and failed
when used in vivo. Posaconazole and ravuconazole have good activity in vitro. The overall rate of
mortality of mucormycosis is approximately 40%.
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INTRODUCTION
Mucormycosis, the third invasive mycosis in
order of importance after candidiasis and asper-
gillosis, is a disease that may be caused by several
species of different genera (Table 1). The term
‘mucormycosis’ is used throughout this review of
infections caused by Mucorales.
The class Zygomycetes is divided into two
orders, Mucorales and Entomophthorales.
Members of the order Mucorales are the aetiolo-
gical agents of the disease traditionally known as
‘mucormycosis’, a fulminant disease with high
rates of morbidity and mortality that mainly
affects immunocompromised patients. However,
species of the order Entomophthorales are
responsible for the chronic subcutaneous disease
observed in immunocompetent patients in trop-
ical and sub-tropical regions [1].
MICROBIOLOGY
Fungi belonging to the order Mucorales fall into
six families (i.e., Mucoraceae, Cunninghamella-
ceae, Mortierellaceae, Saksenaceae, Syncephalas-
traceae and Thamnidaceae), with Mucoraceae
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being the most frequent cause of mucormycosis.
The most important species in order of frequency
are: Rhizopus arrhizus (oryzae), Rhizopus microspo-
rus var. Rhizopodiformis, Rhizomucor pusillus, Cun-
ninghmaella bertholletiae, Apophysomyces elegans,
and Saksenaea vasiformis [2–6].
Mucorales grow well on both non-selective and
selective media. Growth is rapid, with mycelial
elements expanding to cover the entire plate in
only a few days. The mycelium is described as
ﬁbrous or ‘cotton candy-like’ and its growth is so
vigorous that the group has come to be known as
‘lid lifters’.
Identiﬁcation of the agents responsible for
mucormycosis is based on macroscopic and
microscopic morphological criteria, carbohydrate
assimilation and the maximum temperature com-
patible with its growth. Macroscopic criteria are
helpful in establishing a presumptive identiﬁca-
tion, which should be conﬁrmed by microscopic
analysis after staining. Important macroscopic
features are a hyaline appearance, vigorous
growth, light colouration on the reverse side of
the plate (tan to yellow for most species) and
variable degrees of colouration on the sporulating
surface of the colonies (from pure white to tan,
brown, grey or even black). Morphological speci-
ation is microscopic and is based on the demon-
stration of important fungal elements. The family
Mucoraceae may be divided on the basis of the
morphology of the predominant asexual spore-
producing structures (sporangium producers,
sporangiola producers and merosporangium pro-
ducers). Species can be differentiated by elements
such as rhizoids, stolons and columella, which are
usually visualised in the microbiology laboratory
on lactophenol cotton blue-stained slides. Hyphae
are wide, non-septate and measure 10–20 lm in
diameter, with branches which separate from the
main body at almost 90 angles (Figs 1 and 2).
EPIDEMIOLOGY
The incidence of mucormycosis is approximately
1.7 cases per 1000 000 inhabitants per year, which
means 500 patients per year in the USA [7]. Post-
mortem evaluation of the presence of agents
responsible for mucormycosis shows that
mucormycosis is ten- to 50-fold less frequent than
candidiasis or aspergillosis, and that it appears in
one to ﬁve cases per 10 000 autopsies [8–10]. In
Table 1. Classiﬁcation of the aetiological agents respon-
sible for mucormycosis
Family Genus Species
Mucoraceae Absidia A. corymbifera
Apophysomyces A. elegans
Mucor M. circinelloides
M. hiemalis
M. racemosus
M. ramosissimus
M. rouxianus
Rhizopus R. pusillus
R. arrhizus
R. azygosporus
Cunninghamellaceae Cunninghamella C. bertholletiae
Mortierellaceae Mortierella
Saksenaceae Saksenaea S. vasiformis
Syncephalastraceae Syncephalastrum S. racemosum
Thamnidaceae Cokeromyces C. recurvatus
Fig. 1. Macroscopic appearance of a positive culture for
Mucorales.
Fig. 2. Microscopic details of Mucorales.
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patients undergoing allogenic bone marrow trans-
plantation, the incidence may be 2–3% [11,12].
The main risk-factors for the development of
mucormycosis are ketoacidosis (diabetic or other),
iatrogenic immunosuppression, especially when
associated with neutropenia and graft vs. host
disease in haematological patients, use of cortico-
steroids or deferoxamine, disruption of mucocu-
taneous barriers by catheters and other devices,
and even exposure to bandages contaminated by
these fungi [13–19].
Currently, one of the most controversial issues
is the spectacular increase in the number of cases
of mucormycosis in institutions that care for
haemato-oncological patients [12,15,16,20–27].
This increase has generally taken place in patients
and units where broad-spectrum antifungal pro-
phylaxis, especially voriconazole, is used against
Aspergillus [28–30]. A recent study by Kontoyian-
nis et al. [31] describes 27 patients from whom
mucormycosis was retrospectively collected and
compared with a group of 54 patients diagnosed
with invasive aspergillosis during the same per-
iod, and with another group of 54 patients with
the same features who did not suffer from
invasive fungal diseases. Those patients with
mucormycosis yielded isolates of Mucorales with
different genotypes. All clinical isolates were
voriconazole-resistant, and previous prophylaxis
with voriconazole was an independent predictor
of mucormycosis, as were diabetes mellitus and
malnutrition [31]. Mucormycosis was the second
most common invasive mycosis during the study
period and occurred mainly in the lungs (59%)
and sinuses (41%).
PATHOGENESIS
Mucorales invade deep tissues via inhalation of
airborne spores, percutaneous inoculation or
ingestion [1]. They colonise a high number of
patients but do not necessarily cause invasion.
Once the spores have penetrated the lungs or
subcutaneous tissues, they are met by the ﬁrst line
of defence, mononuclear and polynuclear phago-
cytes. The phagocytes of the healthy host are able
to kill the spores of Mucorales by generating
oxidative metabolites and defensins (cationic
peptides) [32–34]. Severely immunocompromised
neutropenic patients and those with phagocyte
dysfunction (e.g., hyperglycaemia) are at greater
risk of mucormycosis. Ketoacidosis decreases the
movement of these phagocytes towards the
source of the infection and their capacity for lysis
by oxidative and non-oxidative mechanisms
[35,36].
Another risk-factor for mucormycosis is the
presence of high concentrations of iron in serum.
Patients treated with deferoxamine have a high
incidence of mucormycosis, probably because
Mucorales use this chelant as a siderophore to
obtain more iron [37]. It is well-known that
administering iron or deferoxamine to animals
infected with Mucorales reduces survival [38–40].
The increased risk of mucormycosis in patients
with ketoacidosis may also be due to the release
of iron bound to proteins [2,41].
If the spores escape phagocytosis, they can
invade vessels, partly by efﬁcacious adherence to
endothelial cells, an ability that Rhizopus oryzae
maintains even when the fungus is not viable
[42].
CLINICAL MANIFESTATIONS
As previously mentioned, mucormycosis occurs
mainly in those patients with diabetes mellitus
and ketoacidosis, in patients with haematological
malignancies [11,13,43–46], especially neutrope-
nia [13,47] or graft vs. host disease, in solid-organ
transplant patients [11,19,20,48–63] and in
patients receiving high doses of corticosteroids
[45]. Treatment with deferoxamine in patients
with iron and aluminium overload has been
associated with mucormycosis, although the
introduction of erythropoietin has signiﬁcantly
decreased the use of deferoxamine, and therefore
this factor is becoming progressively less frequent
in current cases of mucormycosis [1,11,37,40,64–
82]. Mucormycosis is very infrequent in immu-
nocompetent patients, those without risk-factors,
HIV-infected patients, intravenous drug users
and patients with solid-organ tumors
[33,37,41,83–125].
Finally, mucormycosis may occur after trau-
matic inoculation, especially in those cases where
the inoculation is accompanied by contamination
with water and soil. Mortality in these circum-
stances ﬂuctuates between 38% and 80%
[101,126–147].
Mucormycosis (Table 2) manifests most com-
monly in the sinuses (39%), lungs (24%), skin
(19%), brain (9%), and gastrointestinal tract (7%),
in the form of disseminated disease (6%), and
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in other sites (6%) [91]. With the exception of
rhino-cerebral and cutaneous mucormycosis, the
clinical diagnosis of mucormycosis is difﬁcult,
and is often made at a late stage of the disease or
post-mortem [148].
RHINO-CEREBRAL MUCORMYCOSIS
Rhino-cerebral mucormycosis, which should be
termed rhino-sinus mucormycosis, is involved in
between 33% and 50% of all cases of mucormy-
cosis. The most frequent underlying conditions
associated with this clinical manifestation are
uncontrolled diabetes mellitus [1,2,104,150,151,
163–167] and leukaemia [168–172]. It is rare in
solid-organ or haematopoietic stem-cell recipients
[46,48,50,51,57,166,173–180], and occasionally oc-
curs in patients with HIV infection
[108,112,113,117,183] or other conditions [64,
72,73,181,182]. When a healthy patient is infected
after facial trauma, Apophysomyces elegans should
be considered as the ﬁrst presumptive aetiological
agent [83,126,127,132,135,136,144,146,184–187].
Clinical manifestations may start with necrosis
of the palate or sinuses, which may progress
towards the orbit before reaching intra-cranial
structures [188,189]. The most frequent symp-
toms include fever, obnubilation, amaurosis,
proptosis, epistaxis, facial paralysis and signs
of invasion of the trigeminal nerve. Thrombosis
of the cavernous sinuses and cranial invasion
may be consequences of unresolved rhino-sinus
mucormycosis.
Black sores on the palate or nasal mucosa are
very suggestive of mucormycosis in the appro-
priate clinical context, although they may not be
present in 50% of cases [190,191].
Species of the Rhizopus genus are the principal
causes of these clinical manifestations [190].
Despite the rapid course of the disease, some
forms may take weeks or months to develop [192–
199].
The rate of mortality of rhino-orbito-cerebral
mucormycosis is still very high and ranges from
30% to 69% [1,151,180]. Indicators of poor prog-
nosis include a delay in treatment of more than 6
days, evidence of intra-cranial invasion, bilateral
involvement, invasion of the palate, and the
presence of haematological malignancies
[180,200].
RESPIRATORY MANIFESTATIONS
Invasion of the lung is the second most common
clinical manifestation and follows the inhalation
of spores. The most frequent predisposing under-
lying condition has been considered to be haem-
atological malignancy with neutropenia, although
recent studies suggest that diabetes mellitus is the
most frequent underlying condition [2,148,155,
188,201–204].
It is thus not easy to differentiate between
mucormycosis and invasive aspergillosis. Mani-
festations are non-speciﬁc and include fever,
haemoptysis and pleural pain. Mucormycosis
usually occurs in the at-risk population alongside
other common diseases, e.g., cytomegalovirus
infection, bacterial infection or even other fungal
diseases [202,203,205–207]. Endobronchial or tra-
cheal lesions are common [197,208–215], and
vascular involvement of great vessels may be a
cause of fatal haemoptysis [216–224]. Symptoms
may appear after near-drowning episodes [225],
and the differential diagnosis of necrotising
pneumonia or lung abscesses should be consid-
ered [204].
The radiological presentation of mucormycosis
is similar to that of invasive aspergillosis, and
both tend to show vascular invasion and
thrombosis, followed by tissue necrosis. This
Table 2. Clinical manifestations of
mucormycosisClinical manifestation Underlying condition References
Rhino-cerebral Diabetes, ketoacidosis [91,104,149–153]
Pulmonary Neutropenia,
corticosteroid therapy
[91,154,155]
Cutaneous Trauma, diabetes [18,91,156–159]
Gastrointestinal Malnutrition [91,160]
Disseminated disease Deferoxamine, neutropenia,
corticosteroids
[71,75–77,91,161]
Other (central nervous system,
endocarditis, etc.)
Various [91,162]
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presentation includes cuneiform pulmonary
inﬁltrates, pulmonary nodules and cavitated
lesions, including the ‘halo’ sign [226,227].
The rate of mortality associated with pulmon-
ary mucormycosis is high, and may be over 60%.
The rate is higher among patients who do not
receive appropriate treatment (systemic antifun-
gal treatment combined with surgical resection
and control of the underlying disease).
CENTRAL NERVOUS SYSTEM
INVOLVEMENT
Mucormycosis of the central nervous system may
be part of the progression of the disease from a
rhino-orbital route or a clinical manifestation
limited to the central nervous system
[51,104,164,228,229]. Intravenous drug users have
a particular predisposition to mucormycosis lim-
ited to the central nervous system [122,183,230–
235], although this manifestation has proven to be
anecdotal among immunocompetent patients
[85]. The involvement of basal lymph nodes and
the presence of lesions on magnetic resonance
imaging scans are usual [231]. Non-speciﬁc signs
of meningitis may be found in cerebrospinal ﬂuid,
although the culture yield is extremely low
[193,236–238]. Optimal therapy combines medi-
cine and surgery, although a patient has
improved with medical treatment only [183].
CUTANEOUS INVOLVEMENT
The number of cases of cutaneous and soft tissue
mucormycosis has increased during the last few
years. This condition can occur on problem-free
skin or follow the rupture of barriers, e.g.,
through surgery, trauma [147,239–244] or burns
[245–250]. Sometimes, the infection begins at
catheter insertion sites [19,156,159,251,252] or
even after insect bites [156]. It has also been
described after the use of contaminated dressings
[253] and intramuscular injections [254].
Most patients with cutaneous mucormycosis
have underlying conditions such as diabetes
mellitus, solid-organ transplant and leukaemia,
although this clinical manifestation is more com-
mon in patients with no known underlying
diseases [255–257]. In one case review [156],
Adam et al. observed that only 26% of patients
with cutaneous mucormycosis had diabetes
mellitus.
The clinical manifestations of cutaneous
mucormycosis are varied, and range from pus-
tules or vesicles to wounds with wide necrotic
zones (Fig. 3). In their early stages, lesions may be
similar to those present in ecthyma gangrenosum.
In extensive lesions, a cotton-like growth may be
observed over the surface of the tissues, a clinical
sign known as ‘hairy pus’. Rapid diagnosis of
cutaneous mucormycosis may explain the lower
rate of associated mortality.
OTHER CLINICAL MANIFESTATIONS
Mucormycosis can involve any part of the diges-
tive tract [59,160,258–277], with a mortality rate of
98% according to a published series of 25 accu-
mulated cases [59].
Mucormycosis may be the cause of endocarditis
in natural [162,278–280] or prosthetic valves [281]
and has been reported to cause invasion and
obstruction of the great vessels [162]. The clinical
manifestations are extremely rare and the rate of
mortality is very high [58,281–283].
The agents responsible for mucormycosis can
affect the kidneys and, in these cases, nephrec-
tomy is an essential part of treatment [56,109,284–
288].
Osteomyelitis is another rare form of mucormy-
cosis, and bone lesions are usually adjacent to
other forms of mucormycosis (Fig. 4). It has been
described at the base of the cranium [289], in the
bones of the feet and hands [290–292], and in the
humerus [293], tibia [294], femur [295] and ver-
tebrae [296]. Mucormycosis is an extremely rare
form of joint infection [297].
Fig. 3. Clinical manifestations of cutaneous mucormycocis.
Bouza et al. Mucormycosis: an emerging disease? 11
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12 (suppl 7), 7–23
Some cases of peritoneal mucormycosis have
been described in patients undergoing continuous
ambulatory peritoneal dialysis. These are usually
complications of previous bacterial peritonitis
[298–302].
DISSEMINATED DISEASE
Disseminated mucormycosis involves more than
two contiguous organs. In 23–62% of the cases, it
occurs in patients with haematological disease
[13,47,64,86, 110,206,207,303–324] and, in most
cases, the patient is deeply immunodepressed
and suffering from neutropenia. Other risk-fac-
tors for dissemination are the use of corticoster-
oids, immunodepression after solid-organ
transplant, chemotherapy and the use of deferox-
amine. The rate of mortality in cases of dissem-
inated mucormycosis is approximately 100%
[1,155, 322,324].
DIAGNOSIS
The diagnosis of mucormycosis is relatively easy
in the case of rhino-orbital and mucocutaneous
involvement. Nevertheless, when deep tissues are
invaded (e.g., in pulmonary mucormycosis), sam-
ples, and therefore a correct diagnosis, are more
difﬁcult to obtain. In patients suffering from
haematological disease with pulmonary manifes-
tations, an ante-mortem diagnosis can be made in
less than 50% of cases [11,13,47,324].
Tests using cultures of clinical samples have
limited sensitivity, and there are many reports of
negative culture results both ante-mortem and
post-mortem. This appears to be due to aggres-
sive processing of the specimen before plating,
especially when the samples are biopsy speci-
mens, which should be cut into small fragments
before plating. Tests using sputum have sensi-
tivity values below 25% in pulmonary forms, and
its speciﬁcity remains unknown, although it is
generally believed to be low.
The presence of wide, non-septate hyphae in
culture or on slides should always be interpreted
with care, as they may represent colonisation.
Thus, conﬁrmation of the clinical form also
requires the combination of symptoms compat-
ible with histological invasion of tissues. Histo-
pathological testing does not provide the genus
and species, and should therefore be complemen-
ted with culture. Histological invasion, partic-
ularly of vessels, by wide, non-septate hyphae
branched at right angles is diagnostic in an
appropriate clinical context (Fig. 5). The probable
diagnosis of mucormycosis requires the combina-
tion of various clinical data and the isolation in
culture of the fungus from clinical samples.
Diagnosis by imaging is also difﬁcult. In cases
of rhino-orbital lesions, simple radiology and
computed tomography scans usually show inva-
sion of the sinuses, displacement of the orbit and
invasion of the surrounding bone structures.
When intra-cranial structures are affected, mag-
netic resonance imaging is the technique of
Fig. 4. Osteomyelitis, a rare form of mucormycosis.
Fig. 5. Histological invasions of vessels, by wide, non-
septate hyphae.
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choice. Pulmonary mucormycosis causes lesions
that may be non-speciﬁc and cannot be differen-
tiated from those of invasive aspergillosis. Chami-
los et al. [23] demonstrated that the presence of
multifocal pulmonary sinusitis that progresses
during anti-Aspergillus therapy suggests
mucormycosis. Advances in molecular biology
would greatly improve diagnostic capability in
this area.
TREATMENT
The treatment of mucormycosis requires a rapid
diagnosis, correction of predisposing factors, sur-
gical resection, debridement and appropriate
antifungal therapy.
As mentioned above, limited diagnostic tools
mean that, in some studies, 50% of cases are
diagnosed only post-mortem [4,9,325]. Therefore,
physicians should be highly suspicious except
when classic cutaneous or rhino-cerebral forms
are involved. Furthermore, a delay in diagnosis
means a worse prognosis for the disease [149].
Predisposing factors that could be addressed
include diabetic ketoacidosis and the suppression
of corticosteroids and deferoxamine.
Rapid and complete surgery, if possible, is the
best treatment for mucormycosis. In fact, partial
resection of necrotic tissue is better than none at
all, although this is easier in the cutaneous and
rhino-cerebral forms than in visceral forms. Very
extended forms, particularly pulmonary and dis-
seminated disease in neutropenic patients, are
impossible to operate on in many cases
[18,149,152].
Surgery combined with the use of antifungal
drugs is always better than antifungal therapy
alone [13,155,284,326–328].
One of the main difﬁculties in studying treat-
ment of mucormycosis is the lack of large clinical
trials. This may be due to the rarity of the disease,
the high cost involved, the difﬁculty in develop-
ing multicentre studies, and the presence of
variables, e.g., surgery, that would interfere with
the interpretation of results. The choice of optimal
antifungal therapy depends on the results of
antifungal susceptibility testing studies, the re-
sults of studies in animal models, and the anec-
dotal experience gained from cases in humans.
Current data, although indirect, point to high-
dose liposomal amphotericin B as the therapy of
choice for this condition. Amphotericin B has
shown variable activity in vitro against agents
responsible for mucormycosis. Liposomal amph-
otericin B is better tolerated and has lower toxicity
[153,171,180,198,329–333]. Liposomal amphoteri-
cin B at 5 mg ⁄ kg has not been shown to be
inferior to higher doses.
Itraconazole, despite its in-vitro activity against
Mucorales [334], and its success in a few clinical
cases [52,335], is considered an inappropriate
choice, and there is evidence of its failure in
patients suffering from mucormycosis
[15,153,307,336,337].
Voriconazole is not active in vitro against
Mucorales [334] and failed when used in vivo
[28,29].
Posaconazole and ravuconazole have good
activity in vitro [334,338–340] and, in animal
models, posaconazole has proven to be superior
to itraconazole but less effective than amphoter-
icin B deoxycholate [307,338]. Recent studies
indicate that compassionate use of posaconazole
is effective in clinical failures with amphotericin B
and other treatments [334,336,338,340–343]. Cur-
rently, it is the most promising therapeutic alter-
native to amphotericin B.
Caspofungin has poor in-vitro activity against
the agents responsible for mucormycosis, but an
in-vitro ⁄ in-vivo correlation has not been well
established. Caspofungin proved to be active
in vitro by inhibiting the (1 ﬁ 3)-b-D-glucan
synthetase of Rhizopus oryzae, and in an experi-
mental model of disseminated mucormycosis
caused by this microorganism, low-dose caspo-
fungin improved the survival of mice with
mucormycosis induced by diabetic ketoacidosis.
Some authors consider that further studies should
be done to determine the potential role of caspo-
fungin in mucormycosis [344], as there may be a
synergy between caspofungin and amphotericin B
lipid complex [331].
In an experimental murine model of dissemin-
ated mucormycosis, caused by Rhizopus oryzae,
amphotericin B lipid complex was combined with
caspofungin. The combination led to a higher rate
of survival than with each drug used separately,
although it did not reduce the fungal burden in
tissue and was no more effective as prophylaxis
[331]. Overall, clinical experience with caspofun-
gin in mucormycosis is very limited and, cur-
rently, there is not enough evidence to
recommend its use in the treatment of cases of
mucormycosis.
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Other echinocandins, e.g., micafungin, have
shown good results in isolated cases of mucormy-
cosis [26].
Other therapeutic alternatives include the use
of iron chelants other than deferoxamine, and
hyperbaric oxygen (especially in patients with
rhino-cerebral forms), although the efﬁcacy of
both alternatives must be demonstrated in clinical
trials, which are difﬁcult to perform at present
[345–348]. Cytokines such as gamma interferon or
granulocyte–macrophage colony-stimulating fac-
tor have also been used to treat mucormycosis
[349,350].
OUTCOME
The overall rate of mortality of mucormycosis is
approximately 40%, but this rate depends on the
clinical presentation of the disease, the underlying
disease, surgery, and the extent of the infection
[18,151,188,351].
Survival rates vary according to the focus of the
infection: cutaneous isolated, 90%; sinusitis with-
out cerebral involvement, 87%; rhino-cerebral
manifestation, 45%; pulmonary forms, 36%; focal
cerebral manifestation, 33%; disseminated dis-
ease, 16%; and gastrointestinal involvement,
10%.
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